We are live on ! Find out more
CELG.RT

Bristol-Myers Squibb Rights

16 hedge funds and large institutions have $150K invested in Bristol-Myers Squibb Rights in 2023 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 4 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% less ownership

Funds ownership: 0.03%0.03% (-0%)

4% less capital invested

Capital invested by funds: $156K → $150K (-$5.96K)

11% less funds holding

Funds holding: 1816 (-2)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 2

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 4

Holders
16
Holders Change
-2
Holders Change %
-11.11%
% of All Funds
0.25%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
Increased
Reduced
4
Closed
2
Calls
Puts
Net Calls
Net Calls Change

CELG.RT Hedge Fund Activity: Q3 2023 in Review

16 of the 6,303 institutional investors tracked by Wall St. Rank reported a position in Bristol-Myers Squibb Rights (CELG.RT) for Q3 2023, worth a combined $150K — down 3.8% from $156K a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of CELG.RT and 0 opened new positions — a net loss of 2 holders — while 4 trimmed existing stakes and 0 added.

The largest seller was Susquehanna International Group, cutting an estimated $586.

  • 16 institutional investors held Bristol-Myers Squibb Rights (CELG.RT) as of Q3 2023, down from 18 in Q2 2023.
  • Funds reported $150K of Bristol-Myers Squibb Rights stock for Q3 2023, down 3.8% quarter-over-quarter.
  • 0 funds opened new Bristol-Myers Squibb Rights positions in Q3 2023 and 2 closed out, a net change of -2 holders.
  • The largest Bristol-Myers Squibb Rights seller in Q3 2023 was Susquehanna International Group, an estimated $586 sold.

Based on aggregated 13F filings for Q3 2023.